|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013216,
umls-concept:C0027651,
umls-concept:C0242957,
umls-concept:C0256022,
umls-concept:C0332293,
umls-concept:C0441800,
umls-concept:C0449438,
umls-concept:C0458083,
umls-concept:C0597357,
umls-concept:C0600558,
umls-concept:C0681890,
umls-concept:C1516213,
umls-concept:C1522609,
umls-concept:C1554112,
umls-concept:C2745888
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-1-19
|
|
pubmed:abstractText |
The aim of this study was to evaluate the predictive value of five different biological factors in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy: (1) tumour grade scored according to the Elston-Ellis classification, (2) hormonal receptor (HR) status; (3) tumour cell proliferation evaluated by Ki-67 staining, (4) HER-2 and topoisomerase II alpha (TopoIIalpha) expression evaluated by immunohistochemistry (IHC), (5) HER-2 and TopoIIalpha amplification evaluated by real-time polymerase chain reaction (PCR). 119 patients with operable breast cancer were treated with six cycles of FEC (100 5-fluorouracil (5-FU) 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2). Tumour response was assessed clinically and by computed tomography (CT) scan, then by pathological assessment. The clinical overall response (OR) was 80%, with 19% of complete responders (CR). The radiological OR was 71%, with 16% of CR. A pathological CR was demonstrated in 13% of the patients according to the Sataloff classification. In the multivariate analysis, the absence of HR expression and Ki-67 > or = 20% were predictive for a clinical CR. A high tumour grade was predictive for a pathological CR. Overexpression or amplification of HER2 or Topollcalpha were not predictive of response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anthracyclines,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II,
http://linkedlifedata.com/resource/pubmed/chemical/DNA topoisomerase II alpha,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cell Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0959-8049
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
205-11
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:14728934-Adult,
pubmed-meshheading:14728934-Aged,
pubmed-meshheading:14728934-Anthracyclines,
pubmed-meshheading:14728934-Antigens, Neoplasm,
pubmed-meshheading:14728934-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14728934-Breast Neoplasms,
pubmed-meshheading:14728934-Chemotherapy, Adjuvant,
pubmed-meshheading:14728934-Cyclophosphamide,
pubmed-meshheading:14728934-DNA Topoisomerases, Type II,
pubmed-meshheading:14728934-DNA-Binding Proteins,
pubmed-meshheading:14728934-Epirubicin,
pubmed-meshheading:14728934-Female,
pubmed-meshheading:14728934-Fluorouracil,
pubmed-meshheading:14728934-Hormones,
pubmed-meshheading:14728934-Humans,
pubmed-meshheading:14728934-Ki-67 Antigen,
pubmed-meshheading:14728934-Middle Aged,
pubmed-meshheading:14728934-Polymerase Chain Reaction,
pubmed-meshheading:14728934-Receptor, erbB-2,
pubmed-meshheading:14728934-Receptors, Cell Surface,
pubmed-meshheading:14728934-Tumor Markers, Biological
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.
|
|
pubmed:affiliation |
Department of Medical Oncology, Centre de Lutte Contre le Cancer Paul Strauss, 3 rue de la Porte de l'Hôpital, 67065 Strasbourg Cedex, France. tpetit@strasbourg.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
